About BioAutomation
BioAutomation is a Healthcare company based in Irving (United States) founded in 1999, and was acquired by LGC in May 2018. Developer of oligonucleotide synthesizer and synthesis reagents. The company has 14 employees. The company was acqui-hired. BioAutomation offers products and services including MerMade Synthesizers, Oligo Synthesis Reagents, and NGS Kits and Workflows. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its legal entity is Bioautomation Corp. Its competitors include Ansa Biotechnologies, Twist Bioscience and Mesa Biotech; 3 of its 3 listed competitors have raised funding.
Company details
BioAutomation was founded in 1999 in Irving, United States, within the biotechnology sector. Oligonucleotide synthesizers and reagents are developed, with the MerMade system utilized for column-based synthesis of DNA, RNA, and LNA oligonucleotides using standard or modified chemistries. Synthesis reagents for MerMade are created in partnership with Hongene Biotech, Link Technologies, EMD, and Biosearch Technologies. Operations focus on equipment and chemical solutions for molecular biology applications.
- Headquarters Irving, United States
- Employees 14
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bioautomation.com
- Social LinkedIn X Facebook
- Acquired by LGC (May 2018)
- Legal Name Bioautomation Corp
Products & Services of BioAutomation
BioAutomation offers a comprehensive portfolio of products and services, including MerMade Synthesizers, Oligo Synthesis Reagents, and NGS Kits and Workflows.
Automated tools for oligonucleotide synthesis in research.
Materials for custom DNA and RNA production.
Kits for next-generation sequencing applications.
Investors in BioAutomation
BioAutomation has secured backing from 1 investor. Prominent investors backing the company include LGC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Molecular biology reagents and services are supplied to biotech industries. | 1842 | lgcgroup.com | Teddington, United Kingdom |
Investor details for BioAutomation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioAutomation
2 dated milestones of BioAutomation across 19 years, from founding to its latest funding, stage changes and deals.
- Founded BioAutomation is founded.
- Exit Acquired by LGC.
Competitors of BioAutomation
BioAutomation has 3 listed competitors in our database, 3 of them funded. They include Ansa Biotechnologies, Twist Bioscience and Mesa Biotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ansabio.com | 2017 | Berkeley, United States | $175.5M | 253 | DNA synthesis technology using enzymes is provided. | |
| twistbioscience.com | 2013 | San Francisco, United States | $245.81M | 919 | Synthetic DNA is synthesized via a semiconductor-based platform. | |
| mesabiotech.com | 2009 | San Diego, United States | $26.8M | 131 | Point-of-care molecular diagnostic kits are developed and supplied. |
Detailed competitors of BioAutomation
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BioAutomation (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioautomation
Complete news archive for BioAutomation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioAutomation
BioAutomation was founded in 1999.
BioAutomation is headquartered in Irving, United States. It is registered at Irving, Texas, United States.
BioAutomation has 14 employees.
BioAutomation was founded in 1999 in Irving, United States, within the biotechnology sector. Oligonucleotide synthesizers and reagents are developed, with the MerMade system utilized for column-based synthesis of DNA, RNA, and LNA oligonucleotides using standard or modified chemistries. Synthesis reagents for MerMade are created in partnership with Hongene Biotech, Link Technologies, EMD, and Biosearch Technologies. Operations focus on equipment and chemical solutions for molecular biology applications.
BioAutomation's top competitors include Twist Bioscience, Ansa Biotechnologies and Mesa Biotech.
BioAutomation offers MerMade Synthesizers, Oligo Synthesis Reagents, and NGS Kits and Workflows.
BioAutomation has 1 investor. Key investors include LGC.
BioAutomation operates through Bioautomation Corp.
Yes. BioAutomation was acquired by LGC in May 2018.